Key result
Acute myelogenous leukemia is linked to hypocholesterolemia in ~55% of patients at diagnosis.
Observational (n=85)
Plasma-cholesterol concentrations were determined in 85 acute myelogenous leukemia patients. Measurements were repeated in 28 cases during remission. Mean plasma-cholesterol concentration (+/- SD) at diagnosis was 3.95 mmol/l (+/- 1.29). 47 patients (55.3%) had hypocholesterolemia (less than 3.87 mmol/l). Among the main clinical, hematologic and biochemical parameters, only high leukocyte counts were correlated with hypocholesterolemia. As far the FAB subtypes are concerned, the lowest cholesterol levels were observed in leukemias with monocytic component. However, although the same FAB subtypes showed significantly higher leucocytes counts than the other subtypes, both parameters were independently related to low cholesterol levels. Remission was associated with a significant increase in cholesterol levels in those patients with low cholesterol concentrations or high leukocyte counts at diagnosis. These results support the idea that initial hypocholesterolemia in acute myelogenous leukemia is related to the tumoral mass present at diagnosis.
No takes yet. Share an insight, caveat, or question.
Reverter et al. (1988) conducted an observational in Acute myelogenous leukemia (n=85). High leukocyte counts and monocytic FAB subtypes vs. Other FAB subtypes, lower leukocyte counts, or remission state was evaluated on Hypocholesterolemia (<3.87 mmol/l). Acute myelogenous leukemia was associated with hypocholesterolemia (present in 55.3% of patients), which independently correlated with high leukocyte counts and monocytic subtypes at diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: